These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34183205)

  • 1. Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes.
    Carnalla M; Torres-Ibarra L; Barrientos-Gutiérrez T; Cruz-Valdez A; Muñoz N; Herrero R; Stanley M; Nyitray A; Salmerón J; Lazcano-Ponce E
    Vaccine; 2021 Jul; 39(32):4419-4422. PubMed ID: 34183205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
    Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
    Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
    Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
    Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
    Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
    Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
    J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
    Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
    PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
    Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.
    Mesher D; Panwar K; Thomas SL; Beddows S; Soldan K
    BMJ Open; 2016 Feb; 6(2):e009915. PubMed ID: 26868944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
    Hoes J; Woestenberg PJ; Bogaards JA; King AJ; de Melker HE; Berkhof J; Hoebe CJPA; van der Sande MAB; van Benthem BHB;
    Clin Infect Dis; 2021 Mar; 72(5):e103-e111. PubMed ID: 33249475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination.
    Lehtinen T; Söderlund-Strand A; Petäjä T; Eriksson T; Jokiranta S; Natunen K; Dillner J; Lehtinen M
    J Infect Dis; 2017 Nov; 216(8):966-968. PubMed ID: 28968844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
    J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
    Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
    Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
    J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
    Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
    PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women.
    van Eer K; Middeldorp M; Dzebisasjvili T; Lamkaraf N; de Melker HE; Steenbergen RDM; King AJ
    J Infect Dis; 2023 Oct; 228(8):1012-1022. PubMed ID: 36988110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
    Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
    Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.